유럽의 정밀의료 시장 : 생태계 및 국가별 - 분석과 예측(2024-2034년)

Introduction to Europe Precision Medicine Market

The Europe precision medicine market is projected to reach $118.79 billion by 2034 from $40.75 billion in 2024, at a CAGR of 11.29% during the forecast period of 2024-2034. Advances in genomes, diagnostics, and targeted medicines are driving the precision medicine sector in Europe. Key factors include the growing prevalence of chronic diseases, the integration of digital health resources, and an increased emphasis on personalised healthcare. The creation of customised medicines is being aided by government programs and research partnerships, which is increasing patient results. Furthermore, the care of uncommon illnesses, cardiology, and oncology is changing due to the extensive use of biomarkers, next-generation sequencing, and AI-powered diagnostics. Precision medicine is being adopted more quickly in a variety of healthcare settings thanks to the region's robust healthcare infrastructure and rising awareness of personalised treatment.

Market Introduction

From one-size-fits-all therapies to highly customised therapeutic options, the precision medicine market in Europe is drastically changing the healthcare environment. More specialised methods of diagnosing and treating diseases have been made possible by technological advancements, especially in the fields of genomics, next-generation sequencing, and biomarker identification. Personalised therapies are greatly improving patient outcomes in uncommon genetic disorders, cardiovascular diseases, and oncology. By promoting policies that are helpful and making significant investments in research and development, European governments have been instrumental in this change. While maintaining strict guidelines for patient privacy and data security, regulatory bodies are expediting the approval procedures for precision treatments.

The market is further bolstered by strategic alliances among pharmaceutical companies, biotech firms, and academic institutions, fostering an ecosystem of innovation and collaborative research. Digital health tools and artificial intelligence are increasingly integrated into clinical workflows, enhancing diagnostic accuracy and treatment customization. Despite challenges such as the high cost of advanced technologies, regulatory complexities, and the need for robust healthcare infrastructure, the momentum behind precision medicine remains strong. Europe's commitment to personalized healthcare, underpinned by public funding and private investment, positions the region as a global leader in redefining clinical practices and delivering patient-centric care.

Market Segmentation

Segmentation 1: by Ecosystem

• Applied Science
• Precision Diagnostics
• Digital Health and Information Technology
• Precision Therapeutics

Segmentation 2: by Region

• Europe
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Rest-of-Europe

Market Trends, Drivers and Challenges of Europe Precision Medicine Market

Advances in genetics, artificial intelligence, and health technology that allow for individualised treatment options are driving a rapid evolution of the precision medicine business in Europe. Especially in oncology and uncommon disorders, the combination of next-generation sequencing and biomarker development is promoting early detection and focused treatments. The market is expanding thanks to government programs, more financing for healthcare innovation, and cooperative research activities. The market is expanding due to ageing populations, an increase in the prevalence of chronic diseases, and a need for more efficient treatment plans. However, obstacles to wider adoption include expensive costs, intricate legal frameworks, and data privacy issues. It takes large infrastructure investments and patient education to incorporate precision medicine into traditional healthcare systems. Notwithstanding these obstacles, technological developments and strategic alliances between biotech, pharmaceutical, and academic organisations are opening the door to a more cohesive and effective precision medicine ecosystem, which will eventually lead to better patient outcomes and a shift in Europe towards individualised healthcare solutions.

How can this report add value to an organization?

Product/Innovation Strategy: The report offers in-depth insights into the latest technological advancements in precision medicine, enabling organizations to drive innovation and develop cutting-edge products tailored to market needs.

Growth/Marketing Strategy: By providing comprehensive market analysis and identifying key growth opportunities, the report equips organizations with the knowledge to craft targeted marketing strategies and expand their market presence effectively.

Competitive Strategy: The report includes a thorough competitive landscape analysis, helping organizations understand their competitors' strengths and weaknesses and allowing them to strategize effectively to gain a competitive edge in the market.

Key Market Players and Competition Synopsis

Profiled companies have been selected based on inputs gathered from primary experts, as well as analyzing company coverage, product portfolio, and market penetration.

Some prominent names established in this market are:

• Almac Group Ltd.
• ANGLE plc
• F. Hoffmann-La Roche Ltd.
• Merck KGaA
• QIAGEN N.V.

Table of Contents

1 Market Overview

• 1.1 Market Definition
• 1.2 Precision Medicine: A Frontier in the Genesis of Patient-Centric Medicine
• 1.3 Precision Medicine: Remodeling the One-Size-Fits-All Theory to Individually Tailored Therapy
• 1.4 Initiatives and Programs
• 1.5 Precision Medicine: Enabling Technologies and Applications
  • 1.5.1 Innovators
    • 1.5.1.1 3D DNA Printing
      • 1.5.1.1.1 Introduction
      • 1.5.1.1.2 Role of 3D DNA Printing
    • 1.5.1.2 RNA-Seq
      • 1.5.1.2.1 Introduction
      • 1.5.1.2.2 Role of RNA-Seq in Precision Medicine
      • 1.5.1.2.3 Key Players
    • 1.5.1.3 4D Molecular Imaging
      • 1.5.1.3.1 Introduction
      • 1.5.1.3.2 Role of 4D Molecular Imaging in Precision Medicine
      • 1.5.1.3.3 Key Players
  • 1.5.2 Early Adopters
    • 1.5.2.1 CRISPR
      • 1.5.2.1.1 Introduction
      • 1.5.2.1.2 Role of CRISPR in Precision Medicine
      • 1.5.2.1.3 Key Players
    • 1.5.2.2 Blockchain
      • 1.5.2.2.1 Introduction
      • 1.5.2.2.2 Role of Blockchain in Precision Medicine
      • 1.5.2.2.3 Key Players
    • 1.5.2.3 Imaging Informatics
      • 1.5.2.3.1 Introduction
      • 1.5.2.3.2 Role of Imaging Informatics in Precision Medicine
      • 1.5.2.3.3 Key Players
  • 1.5.3 Early Majority
    • 1.5.3.1 Artificial Intelligence (AI)
      • 1.5.3.1.1 Introduction
      • 1.5.3.1.2 Role of Artificial Intelligence in Precision Medicine
      • 1.5.3.1.3 Key Players
    • 1.5.3.2 Circulating Free DNA (cfDNA)
      • 1.5.3.2.1 Introduction
      • 1.5.3.2.2 Role of cfDNA in Precision Medicine
      • 1.5.3.2.3 Key Players
    • 1.5.3.3 Big Data
      • 1.5.3.3.1 Introduction
      • 1.5.3.3.2 Role of Big Data in Precision Medicine
      • 1.5.3.3.3 Key Players
    • 1.5.3.4 Next-Generation Sequencing (NGS)
      • 1.5.3.4.1 Introduction
      • 1.5.3.4.2 Role of NGS in Precision Medicine
      • 1.5.3.4.3 Key Players
    • 1.5.3.5 Health Informatics
      • 1.5.3.5.1 Introduction
      • 1.5.3.5.2 Role of Health Informatics in Precision Medicine
      • 1.5.3.5.3 Key players
    • 1.5.3.6 Bioinformatics
      • 1.5.3.6.1 Introduction
      • 1.5.3.6.2 Role of Bioinformatics in Precision Medicine
      • 1.5.3.6.3 Key Players
  • 1.5.4 Late Majority
    • 1.5.4.1 Polymerase Chain Reactions (PCR)
      • 1.5.4.1.1 Introduction
      • 1.5.4.1.2 Role of PCR in Precision Medicine
      • 1.5.4.1.3 Key players
    • 1.5.4.2 Microarray
      • 1.5.4.2.1 Role of Microarray in Precision Medicine
      • 1.5.4.2.2 Key Players

2 Market: Industry Outlook

• 2.1 Precision Medicine Market: Ecosystem Analysis
• 2.2 Market Trends
  • 2.2.1 Integrating Advanced Imaging for Enhanced Diagnostics and Treatment
  • 2.2.2 Emergence of Biobanks as a Cornerstone of Precision Medicine
• 2.3 Industry Insights
  • 2.3.1 Patent Analysis
  • 2.3.2 Pipeline Analysis
  • 2.3.3 Legal Requirements and Framework by the EMA
• 2.4 Ecosystem Summary

3 Region

• 3.1 Overview
• 3.2 Europe
  • 3.2.1 Regional Overview
  • 3.2.2 Driving Factors for Market Growth
  • 3.2.3 Factors Challenging the Market
    • 3.2.3.1 Europe Precision Medicine Market (by Ecosystem),
  • 3.2.4 Germany
    • 3.2.4.1 Germany Precision Medicine Market (by Ecosystem),
  • 3.2.5 France
    • 3.2.5.1 France Precision Medicine Market (by Ecosystem)
  • 3.2.6 Italy
    • 3.2.6.1 Italy Precision Medicine Market (by Ecosystem),
  • 3.2.7 U.K.
    • 3.2.7.1 U.K. Precision Medicine Market (by Ecosystem),
  • 3.2.8 Spain
    • 3.2.8.1 Spain. Precision Medicine Market (by Ecosystem),
  • 3.2.9 Rest-of-Europe
    • 3.2.9.1 Rest-of-Europe Precision Medicine Market (by Ecosystem)

4 Competitive Landscape

• 4.1 Competitive Landscape
  • 4.1.1 Synergistic Activities
• 4.2 Company Profiles
  • 4.2.1 Almac Group
    • 4.2.1.1 Overview
    • 4.2.1.2 Top Products/Services
    • 4.2.1.3 Top Competitors
    • 4.2.1.4 Analyst View
  • 4.2.2 ANGLE plc
    • 4.2.2.1 Overview
    • 4.2.2.2 Top Products
    • 4.2.2.3 Top Competitors
    • 4.2.2.4 Analyst View
  • 4.2.3 F. Hoffmann-La Roche Ltd.
    • 4.2.3.1 Overview
    • 4.2.3.2 Top Products
    • 4.2.3.3 Top Competitors
    • 4.2.3.4 Analyst View
  • 4.2.4 Merck KGaA
    • 4.2.4.1 Overview
    • 4.2.4.2 Top Products
    • 4.2.4.3 Top Competitors
    • 4.2.4.4 Analyst View
  • 4.2.5 QIAGEN N.V.
    • 4.2.5.1 Overview
    • 4.2.5.2 Top Products
    • 4.2.5.3 Top Competitors
    • 4.2.5.4 Analyst View
  • 4.2.6 bioMerieux SA
    • 4.2.6.1 Overview
    • 4.2.6.2 Top Products
    • 4.2.6.3 Top Competitors
    • 4.2.6.4 Analyst View
  • 4.2.7 Sanofi S.A.
    • 4.2.7.1 Overview
    • 4.2.7.2 Top Products
    • 4.2.7.3 Top Competitors
    • 4.2.7.4 Analyst View
  • 4.2.8 Randox Laboratories Ltd.
    • 4.2.8.1 Overview
    • 4.2.8.2 Top Products
    • 4.2.8.3 Top Competitors
    • 4.2.8.4 Analyst View
  • 4.2.9 GSK plc
    • 4.2.9.1 Overview
    • 4.2.9.2 Top Products
    • 4.2.9.3 Top Competitors
    • 4.2.9.4 Analyst View
  • 4.2.10 Novartis AG
    • 4.2.10.1 Overview
    • 4.2.10.2 Top Products
    • 4.2.10.3 Top Competitors
    • 4.2.10.4 Analyst View
  • 4.2.11 Menarini Silicon Biosystems
    • 4.2.11.1 Overview
    • 4.2.11.2 Top Products
    • 4.2.11.3 Top Competitors
    • 4.2.11.4 Analyst View

5 Research Methodology

• 5.1 Precision Medicine Market: Research Methodology
  • 5.1.1 Data Sources
    • 5.1.1.1 Primary Data Sources
    • 5.1.1.2 Secondary Data Sources
  • 5.1.2 Data Triangulation
• 5.2 Market Estimation and Forecast